Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake
Watson's launch for its Oxytrol overactive bladder patch is relying on heavy sampling, the company said during its second quarter investor call Aug. 5
You may also be interested in...
Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May
Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011